$2.56T
Total marketcap
$178.43B
Total volume
BTC 50.05%     ETH 15.82%
Dominance

Alnylam Pharmaceuticals ALNY Stock

147.41 USD {{ price }} -1.246065% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
18.57B USD
LOW - HIGH [24H]
147.22 - 151 USD
VOLUME [24H]
412.67K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.52 USD

Alnylam Pharmaceuticals Price Chart

Alnylam Pharmaceuticals ALNY Financial and Trading Overview

Alnylam Pharmaceuticals stock price 147.41 USD
Previous Close 198.49 USD
Open 197.87 USD
Bid 0 USD x 800
Ask 0 USD x 900
Day's Range 196.77 - 202.88 USD
52 Week Range 134.77 - 242.97 USD
Volume 295.23K USD
Avg. Volume 676.21K USD
Market Cap 25.2B USD
Beta (5Y Monthly) 0.478521
PE Ratio (TTM) N/A
EPS (TTM) -3.52 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 249.95 USD

ALNY Valuation Measures

Enterprise Value 24.45B USD
Trailing P/E N/A
Forward P/E -81.91903
PEG Ratio (5 yr expected) 0.18
Price/Sales (ttm) 22.035606
Price/Book (mrq) N/A
Enterprise Value/Revenue 21.379
Enterprise Value/EBITDA -33.077

Trading Information

Alnylam Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.478521
52-Week Change 47.59%
S&P500 52-Week Change 20.43%
52 Week High 242.97 USD
52 Week Low 134.77 USD
50-Day Moving Average 198.64 USD
200-Day Moving Average 208.02 USD

ALNY Share Statistics

Avg. Volume (3 month) 676.21K USD
Avg. Daily Volume (10-Days) 396.64K USD
Shares Outstanding 124.53M
Float 123.83M
Short Ratio 8.38
% Held by Insiders 0.32%
% Held by Institutions 98.85%
Shares Short 5.05M
Short % of Float 5.37%
Short % of Shares Outstanding 4.05%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -93.13%
Operating Margin (ttm) -68.92%
Gross Margin 83.55%
EBITDA Margin -64.63%

Management Effectiveness

Return on Assets (ttm) -14.43%
Return on Equity (ttm) -1500.66%

Income Statement

Revenue (ttm) 1.14B USD
Revenue Per Share (ttm) 9.33 USD
Quarterly Revenue Growth (yoy) 49.70%
Gross Profit (ttm) 868.6M USD
EBITDA -739073984 USD
Net Income Avi to Common (ttm) -1064915968 USD
Diluted EPS (ttm) -8.9
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.07B USD
Total Cash Per Share (mrq) 16.63 USD
Total Debt (mrq) 1.32B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 3.773
Book Value Per Share (mrq) -2.087

Cash Flow Statement

Operating Cash Flow (ttm) -536556000 USD
Levered Free Cash Flow (ttm) -371195488 USD

Profile of Alnylam Pharmaceuticals

Country United States
State MA
City Cambridge
Address 675 West Kendall Street
ZIP 02142
Phone 617 551 8200
Website https://www.alnylam.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2002

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Q&A For Alnylam Pharmaceuticals Stock

What is a current ALNY stock price?

Alnylam Pharmaceuticals ALNY stock price today per share is 147.41 USD.

How to purchase Alnylam Pharmaceuticals stock?

You can buy ALNY shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Alnylam Pharmaceuticals?

The stock symbol or ticker of Alnylam Pharmaceuticals is ALNY.

Which industry does the Alnylam Pharmaceuticals company belong to?

The Alnylam Pharmaceuticals industry is Biotechnology.

How many shares does Alnylam Pharmaceuticals have in circulation?

The max supply of Alnylam Pharmaceuticals shares is 125.95M.

What is Alnylam Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Alnylam Pharmaceuticals PE Ratio is now.

What was Alnylam Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Alnylam Pharmaceuticals EPS is -3.52 USD over the trailing 12 months.

Which sector does the Alnylam Pharmaceuticals company belong to?

The Alnylam Pharmaceuticals sector is Healthcare.

Alnylam Pharmaceuticals ALNY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
NASDAQ Q 50 NXTQ 737.55 USD
-0.27
737.3 USD 745.3 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD